UK's Ranier gets £8m for spinal implants:
This article was originally published in Clinica
Ranier Technology has secured £8m ($16m) in new capital to fund the development and commercialisation of its motion-preserving spinal implants. Participating in the financing round were new investor Alliance Trust Equity Partners and existing shareholder First Ventures. Cambridge, UK-based Ranier will use the proceeds for the clinical trials and European launch of CAdisc L, a replacement spinal disc for the lumbar region, as well as for the development of CAdisc C, a cervical version of the product.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.